Patents Represented by Attorney, Agent or Law Firm Jeffrey S. Kubinec
-
Patent number: 6710169Abstract: Novel derivatives of cell surface proteins which are homologous to the immunoglobulin superfamily (adhesons) are provided. Amino acid sequence variations are introduced into adheson, the most noteworthy of which are those in which the transmembrane and, preferably, cytoplasmic domains are rendered functionally inactive, and in which adheson extracellular domains replace an immunoglobulin variable region. These variants are useful in therapy or diagnostics, in particular, CD4 variants are therapeutically useful in the treatment of HIV infections.Type: GrantFiled: May 28, 2002Date of Patent: March 23, 2004Assignee: Genentech, Inc.Inventors: Daniel J. Capon, Timothy J. Gregory
-
Patent number: 6406697Abstract: Novel polypeptides are provided, together with methods for making and using them, and nucleic acids encoding them. These polypeptides are useful as cell surface adhesion molecules and ligands, and are useful in therapeutic or diagnostic compositions and methods.Type: GrantFiled: August 5, 1997Date of Patent: June 18, 2002Assignee: Genentech, Inc.Inventors: Daniel J. Capon, Laurence A. Lasky
-
Patent number: 6274142Abstract: The present invention relates to a method and therapeutic composition for the treatment of myocardial infarction comprising administration of a tissue factor protein antagonist and a thrombolytic agent. In addition, the present invention relates to methods of neutralizing coagulation, including in patients with deep vein thrombosis, with anti-tissue factor antibodies.Type: GrantFiled: June 7, 1995Date of Patent: August 14, 2001Assignee: Genentech, Inc.Inventors: Donogh P. O'Brien, Gordon A. Vehar
-
Patent number: 6117655Abstract: Novel derivatives of cell surface proteins which are homologous to the immunoglobulin superfamily (adhesons) are provided. Amino acid sequence variations are introduced into adheson, the most noteworthy of which are those in which the transmembrane and, preferably, cytoplasmic domains are rendered functionally inactive, and in which adheson extracellular domains replace an immunoglobulin variable region. These variants are useful in therapy or diagnostics, in particular, CD4 variants are therapeutically useful in the treatment of HIV infections.Type: GrantFiled: June 1, 1995Date of Patent: September 12, 2000Assignee: Genentech, Inc.Inventors: Daniel J. Capon, Timothy J. Gregory
-
Patent number: 6113896Abstract: A potent serine protease inhibitor capable of inhibiting Factor Xa, Factor XIIa, plasma kallikrein, and human leukocyte elastase is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor Xa, Factor XIIa, plasma kallikrein, or HLE is indicated.Type: GrantFiled: October 4, 1994Date of Patent: September 5, 2000Assignee: Genentech, Inc.Inventors: Robert A. Lazarus, Mark S. Dennis, Jana Seymour Ulmer
-
Patent number: 6028055Abstract: Compounds related to BNP have reduced binding affinity for the natriuretic peptide receptor-C but possess improved or equivalent affinity to the wild type BNP for natriuretic peptide receptor-A. The BNP related compounds are suitable for use in the treatment or prophylaxis of various pathological conditions associated with water or electrolyte imbalance.Type: GrantFiled: October 21, 1997Date of Patent: February 22, 2000Assignee: Genetech, Inc.Inventors: David G. Lowe, Jill R. Schoenfeld
-
Patent number: 5880256Abstract: A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.Type: GrantFiled: March 3, 1995Date of Patent: March 9, 1999Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Robert A. Lazarus
-
Patent number: 5874407Abstract: The invention provides compositions having a Factor VIIa active site inhibitor domain and a tissue factor domain for the inhibition of FVIIa. The invention also provides pharmaceutical compositions comprising the novel compositions as well as their use in diagnostic, therapeutic, and prophylactic methods.Type: GrantFiled: September 17, 1997Date of Patent: February 23, 1999Assignee: Genentech, Inc.Inventors: Robert F. Kelley, Robert A. Lazarus, Geoffrey F. Lee
-
Patent number: 5863893Abstract: A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.Type: GrantFiled: March 3, 1995Date of Patent: January 26, 1999Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Robert A. Lazarus
-
Patent number: 5856300Abstract: The present invention provides compositions comprising at least one complement moiety and at least one carbohydrate moiety, and methods of producing such compositions. In particular, the compositions of the invention comprise complement proteins related to the complement receptor type I, and further comprise ligands for intracellular molecules, such as selectins. In a preferred embodiment, the compositions comprise a complement-related protein in combination with the Louis X antigen or the sialyl Lewis X antigen. The compositions of the invention have use in the diagnosis or therapy of disorders involving complement activity and inflammation. Pharmaceutical compositions are also provided for treating or reducing inflammation mediated by inappropriate complement activity and intercellular adhesion.Type: GrantFiled: November 13, 1995Date of Patent: January 5, 1999Assignee: T Cell Sciences, Inc.Inventors: Charles W. Rittershaus, Carol A. Toth
-
Patent number: 5846932Abstract: Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.Type: GrantFiled: June 6, 1995Date of Patent: December 8, 1998Assignee: Genentech, Inc.Inventors: David G. Lowe, Brian C. Cunningham, David Oare, Robert S. McDowell, John P. Burnier
-
Patent number: 5843895Abstract: A potent serine protease inhibitor capable of inhibiting Factor Xa, Factor XIIa, plasma kallikrein, and human leukocyte elastase is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor Xa, Factor XIIa, plasma kallikrein, or HLE is indicated.Type: GrantFiled: May 11, 1995Date of Patent: December 1, 1998Assignee: Genentech, Inc.Inventors: Robert A. Lazarus, Mark S. Dennis, Jana Seymour Ulmer
-
Patent number: 5837516Abstract: The bacterial serine protease, subtilisin BPN', has been mutated so that it will efficiently and selectively cleave substrates containing basic residues. Combination mutants, where Asn 62 was changed to Asp, Gly 166 was changed to Asp (N62D/G166D), and optionally Tyr 104 was changed to Asp had a larger than additive shift in specificity toward substrates containing basic residues. Suitable substrates of the variant subtilisin were revealed by sorting a library of phage particles (substrate phage) containing five contiguous randomized residues. This method identified a particularly good substrate, Asn-Leu-Met-Arg-Lys- (SEQ ID NO: 35), that was selectively cleaved in the context of a fusion protein by the N62D/G166D subtilisin variant. A particularly good substrate for N62D/G166D/Y104D would be Asn-Arg-Met-Arg-Lys- (SEQ ID NO: 76).Type: GrantFiled: July 19, 1995Date of Patent: November 17, 1998Assignee: Genentech, Inc.Inventors: Marcus D. Ballinger, James A. Wells
-
Patent number: 5834244Abstract: A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.Type: GrantFiled: March 3, 1995Date of Patent: November 10, 1998Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Robert A. Lazarus
-
Patent number: 5795954Abstract: A potent serine protease inhibitor capable of inhibiting Factor VIIa, Factor XIa, plasma kallikrein, and plasmin is provided. The inhibitor is provided in a pharmaceutical composition for treatment of diseases where inhibition of Factor VIIa, Factor XIa, plasma kallikrein, or plasmin is indicated.Type: GrantFiled: March 4, 1994Date of Patent: August 18, 1998Assignee: Genentech, Inc.Inventors: Robert A. Lazarus, Mark S. Dennis
-
Patent number: 5786328Abstract: Potent and specific serine protease inhibitors are provided that are capable of inhibiting plasma kallikrein. The inhibitors are provided in pharmaceutical compositions for the treatment of diseases and disorders where inhibition of plasma kallikrein in indicated.Type: GrantFiled: June 5, 1995Date of Patent: July 28, 1998Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Robert A. Lazarus
-
Patent number: 5780285Abstract: The bacterial serine protease, subtilisin BPN', has been mutated so that it will efficiently and selectively cleave substrates containing dibasic residues. A combination mutant, where Asn 62 was changed to Asp and Gly 166 was changed to Asp (N62D/G166D), had a larger than additive shift in specificity toward dibasic substrates. Suitable substrates of the variant subtilisin were revealed by sorting a library of phage particles (substrate phage) containing five contiguous randomized residues. This method identified a particularly good substrate, Asn-Leu-Met-Arg-Lys-, that was selectively cleaved in the context of a fusion protein by the N62D/G166D subtilisin variant. Accordingly, this variant subtilisin may be useful for cleaving fusion proteins with dibasic substrate linkers and processing hormones or other proteins (in vitro or in vivo) that contain dibasic cleavage sites.Type: GrantFiled: March 3, 1995Date of Patent: July 14, 1998Assignee: Genentech, Inc.Inventors: Marcus D. Ballinger, James A. Wells
-
Patent number: 5780265Abstract: Potent and specific serine protease inhibitors are provided that are capable of inhibiting plasma kallikrein. The inhibitors are provided in pharmaceutical compositions for the treatment of diseases and disorders where inhibition of plasma kallikrein in indicated.Type: GrantFiled: June 5, 1995Date of Patent: July 14, 1998Assignee: Genentech, Inc.Inventors: Mark S. Dennis, Robert A. Lazarus
-
Patent number: 5741664Abstract: The bacterial serine protease, subtilisin BPN', has been mutated so that it will efficiently and selectively cleave substrates containing dibasic residues. A combination mutant, where Asn 62 was changed to Asp and Gly 166 was changed to Asp (N62D/G166D), had a larger than additive shift in specificity toward dibasic substrates. Suitable substrates of the variant subtilisin were revealed by sorting a library of phage particles (substrate phage) containing five contiguous randomized residues. This method identified a particularly good substrate, Asn-Leu-Met-Arg-Lys-, that was selectively cleaved in the context of a fusion protein by the N62D/G166D subtilisin variant. Accordingly, this variant subtilisin may be useful for cleaving fusion proteins with dibasic substrate linkers and processing hormones or other proteins (in vitro or in vivo) that contain dibasic cleavage sites.Type: GrantFiled: June 1, 1995Date of Patent: April 21, 1998Assignee: Genentech, Inc.Inventors: Marcus D. Ballinger, James A. Wells
-
Patent number: 5739101Abstract: A tissue factor protein mutant capable of neutralizing the ability of endogenous tissue factor to induce coagulation is provided. A representative tissue factor mutant designated K165A, K166A TF is useful in a method for inhibiting thrombin-induced platelet aggregation in a mammal, either separately or in combination with a thrombolytic agent, an anticoagulant, or a GPII.sub.b III.sub.a inhibitor.Type: GrantFiled: May 15, 1995Date of Patent: April 14, 1998Assignee: Genentech, Inc.Inventors: Soumitra Roy, Gordon A. Vehar